Nanobiotix Provides First Quarter 2025 Operational and Financial Update

Core Viewpoint - Nanobiotix is making significant progress in its clinical development programs, particularly with JNJ-1900 (NBTXR3), and is optimistic about upcoming milestones in cancer treatment [2][5]. Operational Highlights - The company is advancing the NANORAY-312 program in head and neck cancer and has expanded development into lung cancer through the CONVERGE study [2][6]. - The first patient has been dosed in the Phase 2 randomized CONVERGE study for unresectable stage 3 non-small cell lung cancer (NSCLC) [6][7]. - Clinical data presented at major conferences supports the expansion of JNJ-1900 into additional cancer indications, including lung cancer and locally advanced pancreatic cancer [2][6][7]. Financial Updates - As of March 31, 2025, Nanobiotix reported cash and cash equivalents of €39.8 million, which is expected to fund operations into mid-2026 [5][6]. - An amendment to the global licensing agreement for JNJ-1900 has extended the cash runway and reduced operational cash burn [6][7]. Product Overview - JNJ-1900 (NBTXR3) is a novel oncology product utilizing hafnium oxide nanoparticles, designed to induce tumor cell death when activated by radiotherapy [8][9]. - The product is being evaluated across multiple solid tumor indications and has received Fast Track designation from the FDA for specific cancer treatments [9][10]. Collaboration and Strategy - Nanobiotix has engaged in collaborations to expand the development of JNJ-1900, including a partnership with MD Anderson Cancer Center for various clinical studies [10][11].